Seattle-based Juno Therapeutics (Nasdaq: JUNO) has more than doubled the amount of cash it has, giving it a deeper pool of capital for its cancer research.
The company, which is at the forefront of immunotherapy cancer treatments, ended 2015 with $1.22 billion in cash. That's a big jump from the $474 million in cash Juno had at the end of the previous year, according to data released Monday in the company's annual earnings report.
Much of that new money came from an agreement that Juno inked with…Seattle-based Juno Therapeutics (Nasdaq: JUNO) has more than doubled the amount of cash it has, giving it a deeper pool of capital for its cancer research.
The company, which is at the forefront of immunotherapy cancer treatments, ended 2015 with $1.22 billion in cash. That's a big jump from the $474 million in cash Juno had at the end of the previous year, according to data released Monday in the company's annual earnings report.
Much of that new money came from an agreement that Juno inked with…